The CHADS-VASc score is a predictor of no-reflow in patients with non-ST-segment elevation myocardial infarction. Issue 1 (January 2020)

• Record Type: Journal Article
• Authors: Barman, Hasan Ali; Kahyaoglu, Serdar; Durmaz, Eser; Atici, Adem; Gulsen, Kamil; Tugrul, Sevil; Isleyen, Hasan Burak; Yildirim, Mehmet Rifat; Gungor, Baris; Okuyan, Ertugrul; Sahin, Irfan
• Is Part Of: Coronary artery disease. Volume 31:Issue 1(2020:Jan.)
• Publication Date: 2020-01
• Subjects: CHADS-VASc -- no-reflow -- non-ST-segment elevation myocardial infarction; Coronary heart disease -- Periodicals; Coronary Disease -- Indexes; Coronary Disease -- Periodicals; 616.123005
• DOI: 10.1097/MCA.0000000000000781
• Languages: English
• ISSNs: 0954-6928

Abstract

Abstract : This study was performed to evaluate the relationship between the CHA2 DS2 -VASc score and no-reflow (NR) phenomena in patients with non-ST-segment elevation myocardial infarction (NSTEMI). A total number of 428 consecutive patients with NSTEMI were assessed for this study. Patients were divided into 2 groups, those with NR, NR(+) (n=84), and those without NR, NR(-) (n=307), according to their post-PCI, no-reflow status. The CHA2 DS2 -VASc score was significantly higher in the NR(+) group compared to the NR(-) (3.48 ± 1.19 vs 1.81 ± 0.82, P < 0.001). After a multivariate regression analysis, a higher CHA2 DS2 -VASc score (OR: 6.52, 95% CI: 3.51–12.14, P < 0.001), hs-Troponin (OR: 1.077, 95% CI: 1.056–1.099, P< 0.001) and TTG (OR: 1.563, 95% CI: 1.134–2.154, P =0.006) were independent predictors of NR. CHA2 DS2 -VASc score is associated with higher risk of no-reflow in patients with NSTEMI undergoing PCI.